Gennova Biopharmaceuticals’ mRNA-based COVID-19 vaccine has submitted the interim clinical data of the phase-I study to the Central Drugs Standard Control Organisation (CDSCO).

The Vaccine Subject Expert Committee (SEC) reviewed the interim phase-I data and found that HGCO19 was safe, tolerable and immunogenic in the participants of the study.

Gennova submitted the proposed phase-II and phase-III study entitled, “A prospective, multi-centre, randomised, active-controlled, observer-blind, phase-II study seamlessly followed by a phase-III study to evaluate the safety, tolerability and immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects” which was approved by the office of the DCG(I), CDSCO.
https://www.expresspharma.in/indias-first-covid-19-mrna-vaccine-dev...